Big Pharma deserves its reward for coming up with Covid-19 vaccines
Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn
It turns out that Covid-19 vaccines are like the old joke about buses. You wait for ages and then three turn up at the same time. Over the last month, we have seen stunning results from Pfizer, Moderna and Oxford-AstraZeneca. Each vaccine is slightly different, in terms of effectiveness, and how quickly it can be rolled out, but there is now no question that we are close to a mass vaccination programme that should bring the virus under control. Six months ago plenty of experts were arguing it would take five years or more to get a working shot. In fact, it has been done in less than a year.
Don’t throw sand in the wheels
But there’s a problem. Now that we are close to a vaccine, the arguments are starting about who gets it, when, and on what terms. There are complaints about the potential for the drugs companies to make excess profits. And countries such as South Africa and India are calling on the World Health Organisation to suspend patent protection on the vaccines so that they can be manufactured by anyone at cost.
It is easy to understand the arguments for that. A Covid-19 vaccine is needed around the world, and some countries might struggle to afford it. It doesn’t make any sense just to vaccinate the richer countries. If the virus is still rampant around the world it will just come back in more virulent forms. The trouble is, suspending patents, and stopping drug companies from making money from the vaccine, would be a disaster, not just for the shareholders in those businesses, but for the whole world.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Why? Getting a vaccine in less than a year is a huge achievement, and one that has cost vast sums of money, much of it privately funded. If the only reward for that is to have the patent rights taken away, then will the companies make the same kind of effort the next time there is a global epidemic?
Second, some exciting new technologies are emerging. The genetics-based vaccines that seem to be working against Covid-19 can not only be developed far more quickly than traditional shots but may also work against many other conditions as well. We already have vaccines that can work against some form of cancers. Over the next decade the technology that has advanced at rapid speed in this crisis may well turn out to be just as good at dealing with other forms of cancer, dementia, Alzheimer’s, and a whole range of hard-to-treat diseases. But if we don’t allow companies patent protection on the technologies they are developing, then that is far less likely to happen – and we will all be worse off for that.
Whatever the profits, it’s a bargain
Finally, it is immoral. Private companies have done the work on a vaccine, they have risked their own money, and they have devoted time and resources to solving a global crisis. They deserve to be rewarded for that. So do their shareholders. If we start taking one form of property away from companies, then where do we stop? In truth, we should probably reward vaccine makers more than we are right now – for example by extending the patent protection from 20 to 30 years. Given the vast cost of the epidemic in terms of locked-down economies, closed businesses and schools, lost jobs, and broken families, if anything we are paying too little for the science that will get us out of the mess, not too much.
There are far better ways of dealing with the issue of global access. The sums of money are not huge, especially when set against the scale of the challenge. Take a relatively poor country such as South Africa, with one of the worst outbreaks on the continent. Even with Moderna’s vaccine, at £30 a shot, the most expensive so far, it would only cost £1.5bn to vaccinate the entire country. If the government can’t raise that, then aid budgets, and charities, could probably step in and fill the gap. If the poorest 20% of the global population needs help paying for the vaccine, then the G20, representing the richest countries in the world, could easily step in with an emergency funding programme. That way we still get the vaccine out around the world, and we also properly reward the companies that made it.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Matthew Lynn is a columnist for Bloomberg, and writes weekly commentary syndicated in papers such as the Daily Telegraph, Die Welt, the Sydney Morning Herald, the South China Morning Post and the Miami Herald. He is also an associate editor of Spectator Business, and a regular contributor to The Spectator. Before that, he worked for the business section of the Sunday Times for ten years.
He has written books on finance and financial topics, including Bust: Greece, The Euro and The Sovereign Debt Crisis and The Long Depression: The Slump of 2008 to 2031. Matthew is also the author of the Death Force series of military thrillers and the founder of Lume Books, an independent publisher.
-
Family investment companies explained: how the ultra wealthy shield their money from the taxmanWealthy families are increasingly turning to family investment companies to keep more of their money away from HMRC – but what are these arrangements and how do they work?
-
How to boost your pension pot as 35% of UK over 50s face huge retirement savings gapOver 50s are facing a later life with little to no funds - but there are steps you can take now to boost your pot.
-
Yoshiaki Murakami: Japan’s original corporate raiderThe originator of Japanese activism, Yoshiaki Murakami, was disgraced by an insider-trading scandal in 2006. Now, he's back, shaking things up
-
Cash in on the vast growth potential of the companies electrifying the worldOpinion Martin Todd, portfolio manager, head of sustainable equities, Federated Hermes, highlights three electrification companies where he'd put his money
-
Galliford Try has firm foundations for strong growthBuilder Galliford Try has a finger in a wide range of pies, notably important work in the public sector
-
Card Factory is a stand-out small-cap going cheapIn a digital world, we still value the personal touch. That’s good news for Card Factory, whose unique business model is suited to weather all economic storms
-
8 of the best smallholdings for sale nowThe best smallholdings for sale – from a medieval cross-passage farmhouse in Taunton, Somerset, to a former farmhouse with an orchard in the Welsh Marches
-
How much gold does China have – and how to cash inChina's gold reserves are vastly understated, says Dominic Frisby. So hold gold, overbought or not
-
How to invest in undervalued gold minersThe surge in gold and other precious metals has transformed the economics of the companies that mine them. Investors should cash in, says Rupert Hargreaves
-
Debasing Wall Street's new debasement trade ideaThe debasement trade is a catchy and plausible idea, but there’s no sign that markets are alarmed, says Cris Sholto Heaton
